calreticulin exon 9 mutated peptide vaccine (Herlev Hospital)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Namecalreticulin exon 9 mutated peptide vaccine (Herlev Hospital)
Drug Alias NameCALR Long36 peptide vaccine (Herlev Hospital Region Hovedstaden)CALR exon 9-mutated peptide vaccine (Copenhagen University Hospital at Herlev)CALR exon 9-mutated peptide vaccine (Herlev Hospital)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Therapeutic vaccine
Mechanisms of ActionT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsPrimary MyelofibrosisThrombocytosisPolycythemia Vera +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHerlev Hospital
China Registration ClassN/A

Develop Information

Active CompaniesHerlev Hospital
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisThrombocytosisPolycythemia Vera
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A